Evidence map›Paper›PMID 29331939›Full record

ArticleStem cell research2018

Volumetric muscle loss injury repair using in situ fibrin gel cast seeded with muscle-derived stem cells (MDSCs).

Nadine Matthias, Samuel D Hunt, Jianbo Wu, Jonathan Lo, Laura A Smith Callahan, Yong Li, Johnny Huard, Radbod Darabi

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Tissue Engineered 3D Constructs for Volumetric Muscle Loss.Annals of biomedical engineering · 2024
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Muscle degeneration in chronic massive rotator cuff tears of the shoulder: Addressing the real problem using a graphene matrix.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nadine MatthiasCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States.
Samuel D HuntCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States.
Jianbo WuCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States.
Jonathan LoCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States.
Laura A Smith CallahanCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States; The Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States.
Yong LiCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States; Department of Pediatric Surgery, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States.
Johnny HuardDepartment of Orthopedic Surgery, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States.
Radbod DarabiCenter for Stem Cell and Regenerative Medicine (CSCRM) and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), United States; The Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States. Electronic address: radbod.darabi@uth.tmc.edu.
Brown Foundation · USThe University of Texas Health Science Center at Houston · US

Funding

Study of Skeletal Muscle Differentiation in Human iPS Cells by Knock-in ReportersR01AR068293 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DARABI, RADBOD · 2016 to 2020
$1.7M
NIAMS NIH HHS R01 AR068293
6 · The paper itself

Abstract

Volumetric muscle defect, caused by trauma or combat injuries, is a major health concern leading to severe morbidity. It is characterized by partial or full thickness loss of muscle and its bio-scaffold, resulting in extensive fibrosis and scar formation. Therefore, the ideal therapeutic option is to use stem cells combined with bio-scaffolds to restore muscle. For this purpose, muscle-derived stem cells (MDSCs) are a great candidate due to their unique multi-lineage differentiation potential. In this study, we evaluated the regeneration potential of MDSCs for muscle loss repair using a novel in situ fibrin gel casting. Muscle defect was created by a partial thickness wedge resection in the tibialis anterior (TA) muscles of NSG mice which created an average of 25% mass loss. If untreated, this defect leads to severe muscle fibrosis. Next, MDSCs were delivered using a novel in situ fibrin gel casting method. Our results demonstrated MDSCs are able to engraft and form new myofibers in the defect when casted along with fibrin gel. LacZ labeled MDSCs were able to differentiate efficiently into new myofibers and significantly increase muscle mass. This was also accompanied by significant reduction of fibrotic tissue in the engrafted muscles. Furthermore, transplanted cells also contributed to new vessel formation and satellite cell seeding. These results confirmed the therapeutic potential of MDSCs and feasibility of direct in situ casting of fibrin/MDSC mixture to repair muscle mass defects.

Indexed as

AnimalsCell DifferentiationCells, CulturedFibrinFibrosisMiceMuscle, SkeletalRegenerationStem CellsFibrinBio-scaffoldFibrin gelMuscle-derived stem cells (MDSCs)Muscle repairSkeletal muscleVolumetric muscle loss

Identifiers

PMID29331939
PMCPMC5851454
OpenAlexW2782835040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.